Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Mast Cells Point to a New Treatment Target for Asthma

By HospiMedica staff writers
Posted on 05 Mar 2008
A new study has identified an enzyme released by mast cells in the lungs that appears to play a key role in the tightening of airways that is a hallmark of asthma, pointing to a potential new target for treatment against the illness.

Researchers at the Weill Cornell Medical College (New York, NY, USA) examined the rings of bronchial tissue from rodents, and discovered that mast cells in these rings released renin--an enzyme which in turn produces angiotensin, a potent constrictor of the smooth muscle that lines airways--along with other substances. More...
The researchers then attempted to confirm if the same process occurred in human tissue. Using novel technology, they confirmed for the first time that mast cells from human lung tissue release a form of renin that is nearly identical to renin found in human mast cells grown in culture or human kidney renin. The study was published in the January 29, 2008, edition of Proceedings of the U.S. National Academy of Sciences (PNAS).

"Back in 2005, our team was the first to discover that mast cells in the heart released renin locally, which elicited heart arrhythmias by triggering angiotensin production within the heart,” explained co-senior author Dr. Roberto Levi, M.D., D.Sc., a professor of pharmacology. "Now, we've expanded those findings to the lungs, where similar mechanisms appear to work locally to help trigger constriction in the airway.”

"In the heart and now the lungs, this localized production of renin appears to have a profound effect on nearby tissues,” added co-senior author Dr. Randi Silver, Ph.D., an associate professor of physiology and biophysics. "More study is needed, of course, but our finding suggests that drugs that target renin might prove effective agents in dampening asthma or other respiratory diseases. These types of 'renin inhibitors' are, in fact, currently being developed by the pharmaceutical industry right now.”

The researchers suggest that local renin production may also be crucial in diseases marked by tissue fibrosis, besides the previously shown effects of vasoconstriction and bronchoconstriction. By finding agents that dampen the renin-angiotensin cascade locally, be it in the heart or the lung, the researchers hope that a formidable new weapon against disease could be developed.


Related Links:
Weill Cornell Medical College

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.